Empaben L 25/5 mg Tablet

Oral tablet. Typically taken once daily at the same time each day, with or without food, as prescribed by a doctor. Swallow whole with water; do not crush/chew. Maintain hydration and follow diet/exercise advice.

Empagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion via the kidneys. Linagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner.

Prescription-only antidiabetic. Risk of dehydration/low blood pressure (especially elderly or on diuretics); maintain adequate fluids. SGLT2 inhibitors may rarely cause ketoacidosis—seek urgent care for nausea/vomiting, abdominal pain, fast breathing, unusual tiredness. Increased risk of genital mycotic infections and UTIs; maintain hygiene and report symptoms. Temporarily stop before major surgery/acute serious illness as advised. Use caution in kidney impairment; empagliflozin efficacy reduces with low eGFR and may be contraindicated in severe renal failure—doctor to monitor renal function. Rare risk of pancreatitis with DPP-4 inhibitors; stop and consult if severe abdominal pain. Not indicated for type 1 diabetes.

Diuretics (increased dehydration/hypotension), insulin or sulfonylureas (increased hypoglycaemia risk), rifampicin (may reduce linagliptin effect), strong inducers of P-gp/CYP3A4 (may reduce linagliptin exposure), other antidiabetic agents (additive glucose-lowering), alcohol (may increase dehydration/ketoacidosis risk)

Store below 25°C, protected from moisture and direct light. Keep in original blister pack. Keep out of reach of children.

Glyxambi 25/5 Tablet, Jardiance Duo 25/5 Tablet, Empagliflozin 25 mg + Linagliptin 5 mg tablets (generic), Empalina 25/5 Tablet, Empaglin L 25/5 Tablet